Shares of US hematology specialist Disc Medicine closed down 21.9% at $55.95 on Friday, having fallen as much as 39%, on news ...
Novartis today announced final results from the Phase III ALIGN study supporting a slowing decline in kidney function in adults with IgA nephropathy (IgAN) who were treated with Vanrafia (atrasentan).
German generics and consumer healthcare major STADA Arzneimittel and China’s Bio-Thera Solutions, a commercial-stage ...
US late-stage biotech Immunic, which is developing novel oral therapies for neurologic and gastrointestinal diseases, today ...
US dermatology specialist Verrica Pharmaceuticals has announced the appointment of Chris Chapman as its chief commercial ...
With support from the epidemic preparedness organization CEPI, Serum Institute of India (SII), the world's largest vaccine manufacturer, has entered into a licensing arrangement with the University of ...
US biopharma Madrigal Pharmaceuticals, which is focused on delivering novel therapeutics for metabolic dysfunction-associated ...
US biotech giant Amgen today announced the European Commission (EC) has approved Uplinza (inebilizumab) as an add-on ...
US biotech major Biogen (Nasdaq: BIIB) has elected Maria Freire as chair of the board of directors. She will take up the role ...
Shares of BridgeBio Pharma were up 8.3% at $79.41 this morning, after it unveiled promising results for its most hotly ...
South Korea’s Samsung Bioepis has signed a settlement and license agreement with US biotech Regeneron concerning the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results